GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Astria Therapeutics
The shares of Astria, a biotech company focused on treating rare allergic and immune diseases, reflect the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company developing innovative treatments for rare diseases caused by excess kallikrein activity, such as hereditary angioedema. We classify it as an "Immune Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Astria Therapeutics is a biotech company developing antibody-based drugs to treat the rare disease hereditary angioedema. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Astria shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ATXS - Daily change in the company's share price Astria Therapeutics
The volatility of Astria Therapeutics, a biopharmaceutical company focused on rare diseases, reflects the sector's high risks. Change_co is an immediate reaction to clinical trial news. This metric is the basis for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Astria Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ATXS, which focuses on rare disease treatments, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Astria is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Astria's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Astria Therapeutics
Astria Therapeutics' year-to-date performance is a story of developing a therapy for a rare hereditary disease—angioedema. Its market capitalization over the next 12 months depends entirely on the progress of its drug's clinical trials. Positive data could make it a leader in this niche and lead to multiple price increases.
Annual dynamics of market capitalization of the market segment - Pharma immune
Astria Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs to treat rare allergic and inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Astria Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Astria Therapeutics
The value of Astria, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its clinical trials for a drug to treat a rare allergic disease, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Astria Therapeutics is a biotech company developing antibody-based therapies for the rare disease hereditary angioedema (HAE). The chart below illustrates the overall dynamics of the biotech sector, where focusing on orphan diseases can be a successful strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Astria Therapeutics is a clinical-stage biotech company developing treatments for rare allergic diseases. Its stock, like all companies of this type, is entirely dependent on research results. Its performance is characterized by a series of sharp ups and downs driven by news, having nothing to do with market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Astria Therapeutics
Astria Therapeutics is a biotech company developing a therapy for a rare genetic disease. Its weekly stock price, typical for this sector, depends entirely on progress in clinical trials and regulatory announcements.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Astria, like the entire rare disease biotech sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Astria Therapeutics is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
ATXS - Market capitalization of the company Astria Therapeutics
The Astria Therapeutics chart is a curve of hopes for the treatment of rare allergic diseases. This biotech company's market cap reflects investors' faith in its experimental drug for the treatment of hereditary angioedema. Its dynamics reflect the response to clinical trial data.
ATXS - Share of the company's market capitalization Astria Therapeutics within the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company targeting the market for the treatment of a rare inherited disease, angioedema. Its market capitalization is based on the potential of its drug, which could become best-in-class.
Market capitalization of the market segment - Pharma immune
Astria Therapeutics develops drugs for rare diseases. How big is this arena? The chart below shows the overall market capitalization of the immunopharmaceutical sector. Its growth reflects the massive investment and scientific advances in finding treatments for complex and rare immunological conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Astria Therapeutics chart visualizes the hopes for a new treatment for a rare hereditary disease. The company's market cap is based on the potential of its drug for preventing angioedema attacks. This diagram illustrates how a highly specialized development could have a multi-billion dollar market potential.
Book value capitalization of the company, segment and market as a whole
ATXS - Book value capitalization of the company Astria Therapeutics
The book value of Astria Therapeutics, which develops drugs for rare allergic diseases, is its material foundation: R&D laboratories, manufacturing contracts, and financial reserves for clinical trials. The chart below shows how the company built this foundation for its scientific research.
ATXS - Share of the company's book capitalization Astria Therapeutics within the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company whose tangible assets are research laboratories focused on treating rare allergic and inflammatory diseases. The chart shows the share of this specialized R&D infrastructure within its narrow therapeutic niche that this innovative company controls.
Market segment balance sheet capitalization - Pharma immune
Astria Therapeutics is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Astria focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Astria Therapeutics's core assets include laboratories and R&D centers for developing long-acting antibodies for the treatment of rare allergic diseases. The chart below shows how the company is building its scientific and physical capital for its clinical programs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Astria Therapeutics
Astria Therapeutics is a biotech company. Its market valuation reflects pure faith in its platform for creating long-lasting antibodies. The chart visualizes investors' hopes for their scientific approach.
Market to book capitalization ratio in a market segment - Pharma immune
Astria Therapeutics is a biotech company developing drugs to treat rare allergic and immunological diseases. Its valuation is based on the potential of its lead candidate. The chart shows a high premium to its stock, reflecting expectations for success.
Market to book capitalization ratio for the market as a whole
Astria Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare allergic and immunological diseases. Its current valuation, compared to the average, is a pure bet on the success of its lead drug. Investors evaluate its potential, which is unrelated to its current tangible assets.
Debts of the company, segment and market as a whole
ATXS - Company debts Astria Therapeutics
Astria Therapeutics is a clinical-stage biotechnology company focused on treating rare allergic and immunological diseases. This chart shows its financial position. The company has no revenue and funds its research exclusively through equity capital, with its future dependent on the success of clinical trials.
Market segment debts - Pharma immune
Astria Therapeutics is a clinical-stage biotech company focused on treating angioedema, a rare inherited disease. Developing drugs for orphan diseases requires significant but focused investment. This chart shows how the company's debt policy reflects its capital needs for clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company developing treatments for rare diseases. Its operations are entirely dependent on the success of clinical trials. This chart shows the extent to which the company finances its expensive R&D with debt. It is a direct indicator of its financial risk and dependence on external capital.
Market segment debt to market segment book capitalization - Pharma immune
Astria Therapeutics is a biotech company developing drugs to treat rare allergic and immunological diseases. This chart shows the debt burden in the biotech sector, indicating the company's ability to finance its expensive clinical trials in this highly specialized field.
Debt to book value of all companies in the market
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on rare allergic and immunological diseases. Its future depends on the success of its developments and access to capital. This chart of total market debt demonstrates how favorable the investment climate is for funding such long-term and risky projects.
P/E of the company, segment and market as a whole
P/E - Astria Therapeutics
Astria Therapeutics is a biotech company developing antibody-based therapy for the treatment of a rare inherited disease, angioedema. This chart reflects investor expectations for the development of a drug for a niche but highly profitable market. The dynamics depend entirely on the results of clinical trials.
P/E of the market segment - Pharma immune
Astria Therapeutics is a biotech company focused on developing therapies for the rare inherited disease angioedema, which causes sudden and severe swelling. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for the development of drugs for orphan (rare) diseases.
P/E of the market as a whole
Astria Therapeutics is a biotech company developing drugs to treat a rare inherited disease, angioedema. Its valuation depends entirely on the success of its clinical programs. Overall market sentiment, reflected in this chart, has no bearing on the company's performance. Astria's fate is decided by clinical data reports, not inflation reports.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company developing a treatment for the rare disease hereditary angioedema. This chart reflects expectations for its clinical development. The company's valuation is a bet that its drug will be effective and find a niche in the market for this orphan disease.
%20P%2FE%20Astria%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Astria-Therapeutics&v=1772621455699 "Chart of the company's future (projected) P/E Astria Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Astria Therapeutics is a biotech company specializing in developing treatments for rare allergic and immunological diseases. This chart reflects speculative expectations for its clinical programs. Comparing these forecasts with the sector reveals the level of investor confidence in its scientific approach and the commercial potential of its future drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772621455701 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Astria Therapeutics is a clinical-stage biotech developing drugs to treat rare allergic and immunological diseases. Its valuation is based on its future potential. This general risk appetite curve determines how easily companies like Astria can raise capital to fund their research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772621455701 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Astria Therapeutics
Astria Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare allergic and immunological diseases. Its financial performance currently reflects R&D expenses. Future profitability depends on the success of clinical trials and the commercialization of new drugs.
Profit of companies in the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company developing treatments for rare diseases associated with allergic reactions. The company focuses on a narrow but important niche. The immunology sector's profitability chart reflects overall investor interest in this field and demonstrates how advances in understanding the immune system are translating into new therapeutic approaches.
Overall market profit
Astria Therapeutics is a biotechnology company focused on treating rare diseases associated with allergic and immune reactions. The company develops new drugs to improve patients' quality of life. Its work exemplifies how highly specialized scientific research can lead to the creation of important and commercially successful drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Astria Therapeutics
Astria Therapeutics is a biotech company developing drugs to treat angioedema, a rare inherited disease. This chart shows the company's speculative clinical pipeline expectations. Future profitability depends entirely on the success of one key product.
%20profit%20of%20the%20company%20Astria%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Astria-Therapeutics&v=1772621455821 "Graph of future (projected) profit of the company Astria Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company focused on treating rare diseases caused by allergic and immune reactions. This chart shows the projected profit trajectory for the biotech sector. This data allows us to assess the company's potential in the niche market of orphan diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772621455833 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for a clinical-stage biotech company. Astria Therapeutics' profit forecast hinges on the success of its developments in treating rare allergic and immunological diseases. Investor expectations reflected here are based on the potential of its lead drug and the results of future clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772621455843 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Astria Therapeutics
Astria Therapeutics is a clinical-stage biotech company specializing in rare allergic and immunological diseases. It has no product revenue. This chart shows a valuation based entirely on the potential of its lead drug candidate. This is a bet on positive clinical trial results.
P/S market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company developing treatments for rare diseases associated with allergic reactions. The company's valuation is based on the potential of its immunology pipeline. This chart shows the average valuation in the biotech industry, reflecting investor expectations for Astria's future revenue if its clinical programs are successful.
P/S of the market as a whole
Astria Therapeutics is a biotech company focused on treating rare diseases caused by allergic and immune reactions. The company has no commercial products. This chart, which displays the average revenue estimate for Astria Therapeutics, emphasizes that its value is based solely on the potential of its scientific developments and future trial results.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Astria Therapeutics
Astria Therapeutics is a biotechnology company focused on developing treatments for rare allergic and immunological diseases. The company has no commercial products. This chart reflects investor expectations for the future. It shows the market's assessment of the likelihood of success in clinical trials and the potential of its developments.
%20P%2FS%20Astria%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Astria-Therapeutics&v=1772621455916 "The graph of the company's future (projected) P/S Astria Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company developing treatments for the rare disease hereditary angioedema. This chart compares market expectations for its future revenue with those of other immune pharma companies. The valuation reflects investor expectations for the success of its lead drug candidate in clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772621455974 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Astria Therapeutics is a clinical-stage biotechnology company developing drugs to treat rare allergic and immunological diseases. Its future depends on the success of clinical trials. The company's potential to offer new treatments is part of the overall optimism surrounding medical innovation, reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772621456060 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Astria Therapeutics
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on the treatment of rare allergic and immunological diseases. The company may not currently have sales revenue. This graph will begin to reflect revenue after the successful commercialization of its developments.
Sales of companies in the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases associated with allergic and immune reactions. Its lead drug targets hereditary angioedema. This chart shows overall pharmaceutical sales, illustrating the importance and commercial potential of orphan disease research.
Overall market sales
Astria Therapeutics is a biotech company developing a therapy for a rare inherited disease, angioedema. This overall economic activity chart for Astria is important through the lens of funding. For niche biotechs working with rare diseases, access to research capital is a key success factor.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Astria Therapeutics
Astria Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare allergic and immunological diseases. Future revenues are dependent on successful clinical trial results and subsequent approval of its drugs. This chart reflects analyst expectations for the scientific and commercial potential of its developments.
%20sales%20of%20the%20company%20Astria%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Astria-Therapeutics&v=1772621456142 "Schedule of future (projected) sales of the company Astria Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Astria Therapeutics is a biotech company developing drugs to treat rare allergic and immunological diseases. This chart shows projected revenue for the entire biotech sector. While it provides a general overview, for Astria, progress in clinical trials of its targeted therapies is key.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772621456162 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Astria Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare allergic and immunological diseases. Its value is entirely dependent on the success of its developments. This graph, reflecting the overall state of the economy, influences the availability of venture capital and stock market sentiment, which are critical for funding the company's long-term research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772621456185 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Astria Therapeutics
Astria Therapeutics is a clinical-stage biotech focused on treating rare diseases. This chart reflects its financial discipline. It demonstrates how the company manages its significant R&D expenses while striving to develop a drug that will deliver high profitability in the future.
Market segment marginality - Pharma immune
Astria Therapeutics is a clinical-stage biotech company specializing in the treatment of a rare disease, hereditary angioedema. This chart reflects its operational structure, typical for a single-disease biotech. It highlights the high R&D costs involved in developing a targeted drug.
Market marginality as a whole
Astria Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of treatments for allergic and immunological diseases. Its future profitability depends on the success of its clinical developments. This total market return chart serves as a contrast to biotech, where scientific breakthroughs in the treatment of chronic diseases can create enormous value.
Employees in the company, segment and market as a whole
Number of employees in the company Astria Therapeutics
Astria Therapeutics is a biotech company specializing in developing treatments for rare allergic and immunological diseases. This graph shows a small, focused team of scientists. This staff size is typical for a clinical-stage company, and its growth will depend on progress in drug development.
Share of the company's employees Astria Therapeutics within the market segment - Pharma immune
This chart reflects Astria Therapeutics' focus on rare diseases. The company's pharmaceutical sector is focused on developing antibodies for the treatment of hereditary angioedema (HAE). This team of scientists is working to create a long-acting drug to prevent attacks in patients with this rare disease.
Number of employees in the market segment - Pharma immune
Astria Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases associated with allergic and inflammatory reactions. This focus on orphan diseases requires deep scientific expertise. This graph shows how biotechnology is expanding into new therapeutic areas, creating a demand for highly specialized scientists.
Number of employees in the market as a whole
Astria Therapeutics, Inc. is a biotechnology company developing drugs to treat rare allergic and immune diseases. Its success depends entirely on the results of clinical trials. This general work schedule is unrelated to its activities, which are focused on solving specific medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Astria Therapeutics (ATXS)
Astria Therapeutics is a biotech company developing therapies for rare allergic and inflammatory diseases. This chart shows its estimated scientific potential. The astronomical market capitalization per research employee reflects investor expectations for its developments, not the company's current financial performance.
%20of%20the%20company%20Astria%20Therapeutics%20(ATXS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Astria-Therapeutics-ATXS&v=1772621456239 "Chart of market capitalization per employee (in thousands of dollars) of the company Astria Therapeutics (ATXS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Astria Therapeutics is a biotech company focused on treating rare allergic and immunological diseases. Its value is a measure of its scientific potential. The chart shows the enormous value the market places on developments that have the potential to radically change the lives of patients with rare diseases.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772621456256 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Astria Therapeutics is a biotech company developing drugs to treat rare allergic and immunological diseases. This chart shows a high salary per employee, which is typical for R&D companies. The value is determined by the potential of its lead drug candidate and its intellectual property.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772621456380 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Astria Therapeutics (ATXS)
Astria Therapeutics is a clinical-stage biotechnology company developing therapies for rare allergic and immunological diseases. The company is not commercially profitable. This chart shows the net loss (R&D costs) per scientist working on developing new drugs for rare diseases.
%20Chart%20Astria%20Therapeutics%20(ATXS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Astria-Therapeutics-ATXS&v=1772621456400 "Company Profit Per Employee (in thousands of dollars) Chart Astria Therapeutics (ATXS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Astria Therapeutics is a biotech company focused on treating rare diseases related to allergies and immunity. This chart shows the loss per employee during clinical development. It serves as a benchmark for assessing how intensively the company invests in R&D per scientist to advance its niche drugs to approval, compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772621456413 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Astria Therapeutics (ATXS) is a clinical-stage biotech company developing treatments for rare allergic and immunological diseases. Like other R&D biotech companies, this chart shows the company's loss per employee. It reflects how much the company invests in each scientist to advance its drug candidates through costly clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772621456443 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Astria Therapeutics (ATXS)
Astria Therapeutics is a biotechnology company developing drugs to treat rare allergic and immunological diseases. This chart reflects the company's clinical-stage activity. Revenue per employee is not reported, as the company is focused on research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Astria-Therapeutics-ATXS&v=1772621456469 "Sales chart per company employee Astria Therapeutics (ATXS)")
Sales per employee in the market segment - Pharma immune
Astria Therapeutics is a biotech company focused on treating rare allergic and immunological diseases. This chart shows the average revenue per employee in this segment. For a clinical-stage company, this is a benchmark for productivity in a sector where success depends on R&D rather than current sales.
Sales per employee for the market as a whole
Astria Therapeutics is a clinical-stage biotech company specializing in rare allergic and immune diseases. They have no commercial products. This figure would be zero, as their scientific team is entirely focused on R&D and clinical trials, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Astria Therapeutics (ATXS)
Astria Therapeutics is a biotech company specializing in the treatment of rare allergic and immune diseases. The bearish sentiment seen in this chart is a standard bet against R&D biotech companies. Bearish sentiment points to a lack of revenue, high cash burn, and a low probability of clinical trial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Astria-Therapeutics-ATXS&v=1772621456515 "Short Shares Chart for the Company Astria Therapeutics (ATXS)")
Shares shorted by market segment - Pharma immune
Astria Therapeutics is a clinical-stage biotech company developing treatments for rare allergic and immunological diseases. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech companies that lack revenue and are entirely dependent on the success of clinical trials.
Shares shorted by the overall market
Astria Therapeutics (ATXS) is a clinical-stage biotech developing treatments for rare diseases. Its stock is a bet on future success. This chart reflects overall risk appetite. When market pessimism rises, investors are less likely to consider long-term bets, and speculative biotech stocks like ATXS are the first to suffer.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Astria Therapeutics (ATXS)
Astria Therapeutics is a clinical-stage biotech focused on treating rare allergic and immune diseases. This chart measures the level of speculative hope. It shows when the stock is "overheated" (overbought) on expectations of positive data or "oversold" due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Astria-Therapeutics-ATXS&v=1772621456545 "RSI 14 indicator chart for the company's stock Astria Therapeutics (ATXS)")
RSI 14 Market Segment - Pharma immune
Astria Therapeutics is a clinical-stage biotech company specializing in rare immune system diseases. Their lead development is aimed at treating hereditary angioedema (HAE). This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Astria Therapeutics (ATXS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATXS (Astria Therapeutics)
Astria Therapeutics (ATXS) is a clinical-stage biopharmaceutical company specializing in the treatment of the rare autoimmune disease hereditary angioedema (HAE). This chart shows the average Wall Street forecast. It reflects analysts' assessments of the clinical data and commercial potential of their long-acting drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATXS-Astria-Therapeutics&v=1772621456598 "A chart showing analyst consensus forecasts for the expected stock price. ATXS (Astria Therapeutics)")
The difference between the consensus estimate and the actual stock price ATXS (Astria Therapeutics)
Astria Therapeutics (ATXS) is a biotech company developing therapies (antibodies) for the treatment of a rare but severe hereditary angioedema (HAE). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATXS-Astria-Therapeutics&v=1772621456611 "A chart showing the difference between the consensus forecast and the actual stock price. ATXS (Astria Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Astria Therapeutics is a biotech company focused on treating the rare but severe condition hereditary angioedema (HAE). This chart shows analysts' overall expectations for the entire immunopharma sector. It reflects experts' confidence in the growth of the orphan disease market and the success of the company's R&D pipeline.
Analysts' consensus forecast for the overall market share price
Astria Therapeutics is a biotech company specializing in developing treatments for rare allergic and immune diseases, specifically hereditary angioedema. This chart shows the overall risk appetite. For Astria, as a clinical-stage company, overall market optimism is important for raising the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Astria Therapeutics
Astria (ATXS) is a clinical-stage biotech focused on treating a rare allergic disease, hereditary angioedema (HAE). This chart represents pure R&D investment. Its valuation reflects the market's confidence in their lead drug and its potential in this (albeit rare, but competitive) niche.
AKIMA Market Segment Index - Pharma immune
Astria (ATXS) is a clinical-stage biotech focused on immunology; the company is developing a novel, long-acting antibody for the treatment of the rare disease HAE (angioedema). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche (HAE) R&D rate (ATXS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Astria Therapeutics is a biotech company developing treatments for hereditary angioedema (HAE). Its key asset is STAR-0215. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this competitive research company stacks up against the broader economic trends affecting the rare disease sector.
